About Us
Dexcel Pharma USA
formerly known as Edenbridge Pharmaceuticals, is a specialty pharmaceutical company focused on identifying, developing, and marketing prescription pharmaceutical products. Our goal is to create a broad portfolio of limited source branded and generic pharmaceutical products that will provide high-quality, affordable, and accessible alternatives in the healthcare market. Our approach is to work with best-in-class and like-minded industry partners to deliver our products to physicians and patients everywhere.
Founded in 2008, we launched our first product in February 2010 and have sold our commercial products through every major channel of the U.S. prescription pharmaceutical supply chain. In addition, we have a robust product development pipeline that includes 505(b)(2) NDAs, ANDAs, and foreign filings.
2008
Launched first product
2014
First NDA approved
2022
Rebranded to Dexcel Pharma USA
Company founded
2010
First ANDA approved
2021
Acquired by Dexcel Pharma
2024
2008
company founded
2010
launched first product
2014
first ANDA approved
2021
first NDA approved
2022
acquired by Dexcel Pharma USA
2024
rebranded to Dexcel Pharma USA